Top-Rated StocksTop-RatedNASDAQ:MAZE Maze Therapeutics (MAZE) Stock Price, News & Analysis $28.69 +1.01 (+3.65%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$28.68 -0.01 (-0.02%) As of 07/27/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Maze Therapeutics Stock (NASDAQ:MAZE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Maze Therapeutics alerts:Sign Up Key Stats Today's Range$27.69▼$29.0350-Day Range$23.58▼$32.8452-Week Range$12.81▼$53.65Volume269,881 shsAverage Volume537,772 shsMarket Capitalization$1.59 billionP/E RatioN/ADividend YieldN/APrice Target$66.00Consensus RatingBuy Company Overview Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic. Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas. By integrating large‐scale genetic datasets with functional genomics assays, the company seeks to uncover previously unrecognized pathways that can be modulated by small molecules or biologics. Its target selection strategy is designed to deliver higher confidence in clinical proof‐of‐concept studies, and Maze’s research collaborations with academic and industry partners support the advancement of its most promising candidates through preclinical and early clinical stages. Headquartered in South San Francisco, California, Maze Therapeutics operates within a vibrant biotech cluster and draws on a network of scientific advisors and strategic collaborators worldwide. The company is led by a management team with extensive experience in genomics, drug development and translational research. By focusing on genetically validated targets and a disciplined go-to-clinic approach, Maze aims to bring transformative therapies to patients in need while creating value for its shareholders.AI Generated. May Contain Errors. Read More Maze Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreMAZE MarketRank™: Maze Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 621st out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingMaze Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMaze Therapeutics has a consensus price target of $66.00, representing about 130.0% upside from its current price of $28.69.Amount of Analyst CoverageMaze Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Maze Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Maze Therapeutics are expected to decrease in the coming year, from ($2.73) to ($3.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maze Therapeutics is -11.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maze Therapeutics is -11.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaze Therapeutics has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.54% of the float of Maze Therapeutics has been sold short.Short Interest Ratio / Days to CoverMaze Therapeutics has a short interest ratio ("days to cover") of 8.48.Change versus previous monthShort interest in Maze Therapeutics has recently decreased by 0.03%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaze Therapeutics does not currently pay a dividend.Dividend GrowthMaze Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment1.27 News SentimentMaze Therapeutics has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Maze Therapeutics this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added Maze Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Maze Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,887,939.00 in company stock.Percentage Held by Insiders5.30% of the stock of Maze Therapeutics is held by insiders.Percentage Held by InstitutionsMaze Therapeutics has minimal institutional ownership at this time.Read more about Maze Therapeutics' insider trading history. Receive MAZE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maze Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAZE Stock News HeadlinesMaze Therapeutics, Inc. (NASDAQ:MAZE) Receives $66.00 Consensus Price Target from AnalystsJuly 23, 2026 | americanbankingnews.comMaze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE InvestorsJuly 14, 2026 | tipranks.comALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it. | Brownstone Research (Ad)Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $436,809.10 in StockJuly 3, 2026 | insidertrades.comMaze Therapeutics (NASDAQ:MAZE) Insider Sells 7,500 Shares of StockJuly 2, 2026 | insidertrades.comWhat Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?June 29, 2026 | finance.yahoo.comMaze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And RiskJune 13, 2026 | finance.yahoo.comMaze Therapeutics Shareholders Elect Directors, Ratify AuditorJune 10, 2026 | tipranks.comSee More Headlines MAZE Stock Analysis - Frequently Asked Questions How have MAZE shares performed this year? Maze Therapeutics' stock was trading at $41.43 at the beginning of 2026. Since then, MAZE stock has decreased by 30.8% and is now trading at $28.69. How were Maze Therapeutics' earnings last quarter? Maze Therapeutics, Inc. (NASDAQ:MAZE) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.02. The firm had revenue of $20 million for the quarter. When did Maze Therapeutics IPO? Maze Therapeutics (MAZE) raised $140 million in an initial public offering (IPO) on Friday, January 31st 2025. The company issued 8,750,000 shares at a price of $15.00-$17.00 per share. How do I buy shares of Maze Therapeutics? Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2026Today7/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 MAZE's financial health is in the Yellow zone, according to TradeSmith. MAZE has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MAZE Previous SymbolNASDAQ:MAZE CIK1842295 WebN/A Phone(650) 850-5070FaxN/AEmployees121Year Founded2018Price Target and Rating Average Price Target for Maze Therapeutics$66.00 High Price Target$110.00 Low Price Target$46.00 Potential Upside/Downside+130.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$131.12 million Net MarginsN/A Pretax Margin-612.71% Return on Equity-36.62% Return on Assets-31.78% Debt Debt-to-Equity Ratio0.11 Current Ratio17.88 Quick Ratio17.88 Sales & Book Value Annual Sales$167.50 million Price / Sales9.48 Cash FlowN/A Price / Cash FlowN/A Book Value$7.38 per share Price / Book3.89Miscellaneous Outstanding Shares55,350,000Free Float52,412,000Market Cap$1.59 billion OptionableN/A Beta2.14 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:MAZE) was last updated on 7/28/2026 by MarketBeat.com Staff. From Our PartnersMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThe 1974 Kissinger "Secret" Wall Street Never DecodedIn 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...Golden Portfolio | SponsoredWhat Elon told his top shareholders in TexasLate last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...Banyan Hill Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredA storm is comingThe U.S. dollar has sunk to near a four-year low, while the Bureau of Economic Analysis prepares a change to h...Stansberry Research | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
